Clinical Trial

A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-01
Trial Details
NCT Number NCT07604116
Lead Sponsor Synusight Biotech (Shanghai) Co., Ltd.
Conditions Multiple System Atrophy (MSA), Parkinson's Disease (PD)
Enrollment 30 participants
Start Date 2026-06-15
Primary Completion 2026-12 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-30